Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Enriqueta Felip(Institut Català d'Ornitologia), H. Wakelee(Cancer Prevention Institute of California), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari), Caicun Zhou(Tongji University), Nasser K. Altorki(Cornell University), Achim Rittmeyer(Unknown), Martin Reck(German Center for Lung Research), Minu K. Srivastava, Antonio Chella(Azienda Ospedaliera Universitaria Pisana), Eric Vallières(Public Health Agency of Canada), Virginia McNally(Roche (United Kingdom)), Elizabeth Bennett, O. Goloborodko, R. Belleli(Roche (Switzerland)), Meijuan Huang, B.J. Gitlitz
Cited by 251
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k